PAGE-3 Inhibitors
PAGE-3 inhibitors encompass a range of compounds that effectively diminish the activity of PAGE-3 through various biochemical mechanisms. For instance, inhibitors that target kinase activities are particularly pertinent due to the phosphorylation-dependent regulation of PAGE-3. By binding to ATP binding sites, certain inhibitors impede the catalytic activity of kinases responsible for phosphorylating proteins, ultimately leading to a reduction in PAGE-3 activity when its function is dependent on this post-translational modification. Additionally, compounds that specifically obstruct the PI3K/AKT and MAPK/ERK pathways can also result in decreased PAGE-3 activity. These pathways are critical for numerous cellular processes, including protein regulation, and the inhibition of PI3Ks or MEK disrupts the downstream signaling that could be vital for PAGE-3 function. Similarly, inhibition of mTORC1 by certain molecules suppresses protein synthesis and may indirectly lead to the downregulation of PAGE-3.
Moreover, other inhibitors operate by influencing the cellular stress response, proteostasis, and cell cycle progression, all of which can indirectly affect PAGE-3. For example, the inhibition of p38 MAP kinase may reduce the activation of proteins that are regulated as part of the cellular response to stress, potentially including PAGE-3. Proteasome inhibitors, which prevent the degradation of polyubiquitinated proteins, could lead to the functional impairment of PAGE-3 if it is a substrate for ubiquitin-mediated proteasomal degradation. Additionally, by disrupting mitotic spindle formation through the inhibition of Aurora kinases, the cell cycle can be arrested, which could indirectly impair PAGE-3 if it plays a role in cell cycle checkpoints or progression. Furthermore, compounds that inhibit EGFR tyrosine kinase activity also contribute to the inhibition of PAGE-3 by blocking signal transduction pathways that may be critical for the growth and survival of cells in which PAGE-3 is involved.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This kinase inhibitor interferes with ATP binding sites on various protein kinases, thereby reducing phosphorylation activity. PAGE-3, being a phosphoprotein, can be indirectly inhibited due to the reduction in kinase activity, leading to decreased phosphorylation levels and thus functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3Ks, which blocks the PI3K/AKT signaling pathway. As PAGE-3 may be regulated by this pathway, inhibition of PI3Ks can lead to decreased activity of PAGE-3 due to reduced downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that suppresses mTORC1 activity, potentially leading to decreased protein synthesis and indirectly inhibiting proteins regulated by mTORC1, including PAGE-3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor that blocks the MAPK/ERK pathway. PAGE-3, potentially involved in this pathway, can be indirectly inhibited by preventing the pathway's activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This inhibitor targets p38 MAP kinase, which is implicated in stress responses. Inhibition of p38 MAPK can lead to decreased activation of proteins, such as PAGE-3, that may be downstream targets. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that leads to the accumulation of polyubiquitinated proteins and induces cell cycle arrest. PAGE-3, if it undergoes ubiquitination, might be stabilized and functionally impaired due to proteasomal inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Another proteasome inhibitor which can cause the buildup of proteins targeted for degradation. If PAGE-3 is subject to proteasomal degradation, its function could be indirectly inhibited by bortezomib. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK which prevents the activation of ERK. If PAGE-3 is regulated through the ERK signaling pathway, inhibition of MEK can lead to decreased PAGE-3 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
An inhibitor of the c-Jun N-terminal kinase (JNK), which participates in apoptosis and cell proliferation. Inhibition of JNK could lead to altered cell signaling and indirectly inhibit PAGE-3 if it is part of JNK-dependent pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A covalent inhibitor of PI3K, leading to inhibition of the AKT signaling pathway. This inhibition can decrease the activity of proteins such as PAGE-3, which may be regulated by AKT signaling. | ||||||